A case report of acquired hemophilia following COVID-19 vaccine

J Thromb Haemost. 2021 Jun;19(6):1515-1518. doi: 10.1111/jth.15291. Epub 2021 May 10.

Abstract

Acquires hemophilia A (AHA) is rare bleeding condition commonly associated with malignancy, autoimmune disease, or pregnancy. We report a case of a 69-year-old gentleman who developed bleeding symptoms after receiving COVID-19 vaccine. Laboratory testing showed isolated prolongation of the activated partial thromboplastin time, and normal von Willebrand factor. Further testing confirmed the presence of factor VIII inhibitor. To date, no cases of AHA have been reported after exposure to COVID-19 vaccine. There have been two cases of AHA following seasonal flu and H1N1 vaccination, as well as two cases of AHA following COVID-19 infection. We present a summary of these cases and review of literature of autoimmune reactions following vaccination.

Keywords: glucocorticoids; hemophilia A; hemorrhage; immune system; immunosuppression.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • COVID-19 Vaccines
  • COVID-19*
  • Factor VIII
  • Female
  • Hemophilia A* / diagnosis
  • Humans
  • Influenza A Virus, H1N1 Subtype*
  • Male
  • Pregnancy
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • Factor VIII